Increased Oversight Of FDA Coming, Industry Attorney Warns
This article was originally published in The Silver Sheet
Executive Summary
Now that the election is over and Republicans will soon run Congress, expect GOP members to push for FDA reform, a Latham & Watkins partner predicts.
You may also be interested in...
IRB, HIPAA Changes To Be Folded Into 21st Century Cures Bill Next Year
Centralized institutional review board approvals for device trials, and removal of HIPAA privacy provisions that block registry data-sharing are among the ideas that are likely to make it into a draft bill planned for release in January as the next step in the House’s 21st Century Cures initiative.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.